Compare Divis Laboratories with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GLENMARK PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GLENMARK PHARMA DIVIS LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 32.2 12.3 262.4% View Chart
P/BV x 7.3 1.8 414.0% View Chart
Dividend Yield % 0.6 0.6 112.0%  

Financials

 DIVIS LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
GLENMARK PHARMA
Mar-19
DIVIS LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,142712 160.5%   
Low Rs533484 110.2%   
Sales per share (Unadj.) Rs146.6349.6 41.9%  
Earnings per share (Unadj.) Rs33.032.8 100.8%  
Cash flow per share (Unadj.) Rs38.444.3 86.6%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.20.3 356.8%  
Book value per share (Unadj.) Rs222.8198.6 112.2%  
Shares outstanding (eoy) m265.47282.17 94.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.71.7 334.2%   
Avg P/E ratio x25.318.2 139.1%  
P/CF ratio (eoy) x21.813.5 161.8%  
Price / Book Value ratio x3.83.0 124.9%  
Dividend payout %30.36.1 496.1%   
Avg Mkt Cap Rs m222,318168,625 131.8%   
No. of employees `00010.812.0 89.4%   
Total wages/salary Rs m4,56120,561 22.2%   
Avg. sales/employee Rs Th3,616.08,196.0 44.1%   
Avg. wages/employee Rs Th423.81,708.1 24.8%   
Avg. net profit/employee Rs Th814.9768.5 106.0%   
INCOME DATA
Net Sales Rs m38,91598,655 39.4%  
Other income Rs m1,1342,081 54.5%   
Total revenues Rs m40,049100,736 39.8%   
Gross profit Rs m12,61715,858 79.6%  
Depreciation Rs m1,4253,259 43.7%   
Interest Rs m133,346 0.4%   
Profit before tax Rs m12,31311,335 108.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m3,5433,756 94.3%   
Profit after tax Rs m8,7709,250 94.8%  
Gross profit margin %32.416.1 201.7%  
Effective tax rate %28.833.1 86.8%   
Net profit margin %22.59.4 240.4%  
BALANCE SHEET DATA
Current assets Rs m45,35166,968 67.7%   
Current liabilities Rs m6,50740,211 16.2%   
Net working cap to sales %99.827.1 368.0%  
Current ratio x7.01.7 418.5%  
Inventory Days Days12783 152.0%  
Debtors Days Days9581 117.2%  
Net fixed assets Rs m21,16033,322 63.5%   
Share capital Rs m531282 188.1%   
"Free" reserves Rs m58,62555,770 105.1%   
Net worth Rs m59,15656,052 105.5%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m67,832132,888 51.0%  
Interest coverage x926.84.4 21,123.5%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.7 77.3%   
Return on assets %12.99.5 136.6%  
Return on equity %14.816.5 89.8%  
Return on capital %20.817.8 117.0%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35962,998 51.4%   
Fx outflow Rs m9,04222,859 39.6%   
Net fx Rs m23,31740,140 58.1%   
CASH FLOW
From Operations Rs m7,75913,242 58.6%  
From Investments Rs m-4,783-6,990 68.4%  
From Financial Activity Rs m-3,142-7,387 42.5%  
Net Cashflow Rs m-166-2,971 5.6%  

Share Holding

Indian Promoters % 52.0 48.3 107.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 6.9 171.0%  
FIIs % 19.0 34.4 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.5 163.8%  
Shareholders   31,796 56,727 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FULFORD INDIA  JUBILANT LIFE SCIENCES  BIOCON   

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 82 Points Higher; Metal and Realty Stocks Witness Buying(Closing)

Indian share markets ended their trading session marginally higher. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 18, 2019 03:33 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS